Acromegaly--a novel view of the patient. Polish proposals for diagnostic and therapeutic procedures in the light of recent reports

• Published in: Endokrynologia Polska Vol. 65; no. 4; pp. 326 - 331
• Main Authors: Bolanowski, Marek, Ruchała, Marek, Zgliczyński, Wojciech, Kos-Kudła, Beata, Bałdys-Waligórska, Agata, Zieliński, Grzegorz, Bednarczuk, Tomasz, Hubalewska-Dydejczyk, Alicja, Kamiński, Grzegorz, Marek, Bogdan, Daroszewski, Jacek, Waśko, Ryszard, Lewiński, Andrzej
• Format: Journal Article
• Language: English
• Published: Poland Wydawnictwo Via Medica 2014
• Subjects: Acromegaly - diagnosis; Acromegaly - drug therapy; Acromegaly - pathology; Acromegaly - therapy; Adrenalectomy - methods; Dopamine Agonists - therapeutic use; Human Growth Hormone - therapeutic use; Humans; Pituitary Neoplasms - complications; Poland; Prognosis
• ISSN: 0423-104X; 2299-8306
• DOI: 10.5603/EP.2014.0045

is usually delayed and is often associated with the development of various complications causing premature mortality. In patients with hypertension, heart failure, diabetes, and arthropathy that is non-specific for age, attention should be paid to the occurrence of somatic signs of acromegaly. As a screening test, insulin-like growth factor-1 (IGF-1) concentration should be assessed. Further diagnostic and treatment procedures are possible in specialised centres. The first-line therapy is selective transsphenoidal adenomectomy. Patients with a good prognosis related to a surgical removal of the pituitary tumour should be referred only to centres experienced in performing this type of procedure, after pharmacological preparation. Other patients, and those who have not recovered after surgical treatment, should be subjected to long-term pharmacotherapy with long-acting somatostatin analogues. In each case, the complications of acromegaly should be followed-up long-term and actively treated. This proposed new recommendation should be helpful for the management of patients with acromegaly.